<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine the role of bone marrow biopsy (BMBX), performed in association with comprehensive blood and imaging tests, in the evaluation of patients with <z:hpo ids='HP_0001945'>fever</z:hpo> of unknown origin (FUO) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: We reviewed the medical records of 475 hospitalized patients who underwent BMBX in our medical center from January 1, 2005, to April 30, 2010 </plain></SENT>
<SENT sid="2" pm="."><plain>We identified 75 patients who fulfilled the accepted classic Petersdorf criteria for FUO </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent in-hospital investigation for <z:hpo ids='HP_0001945'>fever</z:hpo>, including chest and abdominal computed tomography </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In 20 patients (26.7%), BMBX established the final diagnosis </plain></SENT>
<SENT sid="5" pm="."><plain>Sixteen patients had <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e>, including 8 patients with non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 2 with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, 1 with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, 1 with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and 4 with <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The remaining patients with diagnostic BMBX specimens had <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> (2 patients), <z:e sem="disease" ids="C0740451" disease_type="Disease or Syndrome" abbrv="">granulomatous disease</z:e> (1 patient), and <z:mpath ids='MPATH_654'>hemophagocytic syndrome</z:mpath> (1 patient) </plain></SENT>
<SENT sid="7" pm="."><plain>Multivariate analysis revealed the following as the significant positive predictive parameters for a diagnostic BMBX specimen: male sex (odds ratio [OR], 7.35; 95% confidence interval [CI], 1.19-45.45), clinical <z:hpo ids='HP_0002716'>lymphadenopathy</z:hpo> (OR, 21.98; 95% CI, 1.97-245.66), <z:hpo ids='HP_0001903'>anemia</z:hpo> (OR, 2.21; 95% CI, 1.28-3.80), and <z:mp ids='MP_0002944'>increased lactate dehydrogenase levels</z:mp> (OR, 1.003; 95% CI, 1.001-1.006) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Bone marrow biopsy is still a useful ancillary procedure for establishing the diagnosis of FUO, particularly if used in the appropriate clinical setting </plain></SENT>
<SENT sid="9" pm="."><plain>Clinical and laboratory parameters associated with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic disease</z:e> are predictive of a diagnostic BMBX specimen in patients with FUO </plain></SENT>
</text></document>